Ronald B. Herberman

Intrexon Corporation, USA

Ronald B. Herberman holds an M.D. degree. He became the Founding Director of the University of Pittsburgh Cancer Institute in 1985. In February 1, 2009, he began his new role as the Director Emeritus of the University of Pittsburgh Cancer Institute and a Professor of pathology and medicine. Dr. Herberman is an internationally recognized tumor immunologist. The phenomenon of natural killer (NK) cell-mediated cytotoxicity against tumors was first discovered in Dr. Herberman's laboratory in the early 1970s. He has played a leading role in the development of several other important aspects of tumor immunology. During his 19 years at the NCI, his contributions included the development of evidence for specifics antitumor immunity to human tumors and evidence for the prognostic value of some of these functions, the organization of a national program of immunodiagnostic research and a critical approach to the evaluation of tumor markers, a major role in the development of the Biological Response Modifiers Program of the NCI, and the adoption of a systematic rational approach to the clinical investigation of biological response modifiers. His current research focuses on the systematic evaluation of IL-2-stimulated NK cells for their therapeutic efficacy and prolongation of survival, especially in regard to the use of this strategy in treatment of minimal residual disease following conventional treatment by surgery or chemotherapy. Moreover, his achievements have been recognized by numerous awards, including the Governor of Pennsylvania's Award for Excellence in Science and Medicine, a Lifetime Science Award from the Institute for Advanced Studies in Immunology and Aging, and the Solomon A. Berson Medical Alumni Achievement Award in Clinical Science from his alma mater, New York University. Dr. Herberman was noted as one of the 100 most cited research authors for the period 1981–1990.

Biography Updated on 21 October 2009

Scholarly Contributions [Data Provided by scopus]